Compare EPAM Systems Inc (EPAM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Tango Therapeutics Inc. — how do they compare? EPAM Systems Inc trades at $115.12 (market cap $5.96B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: EPAM Systems Inc is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Tango Therapeutics Inc. for 0 Days on average.
| EPAM | TNGX | |
|---|---|---|
Market Cap | $5.96B | $3.75B |
Volume | 731,369 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $221.40 | $32.90 |
52-Week Low | $76.04 | $7.50 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $5.32B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $114.63, up 1.41% today, with a bullish technical signal and strong fundamental valuation metrics including a P/E of 15.67 and P/S of 1.12. Recent quarterly earnings have consistently beaten expectations, and the company announced a partnership with Wiz to enhance cloud security (PRNewsWire, 2026-08-25).
The outlook is positive with a consensus price target of $119, representing ~4% upside. Key opportunities include AI-native revenue growth exceeding 11% (Seeking Alpha, 2026-09-02), while risks involve slower North American growth and activist pressure for buybacks (Reuters, 2026-08-31).
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
